Multimorbidity UK Medical PG Practice Questions and MCQs
Practice UK Medical PG questions for Multimorbidity. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Multimorbidity UK Medical PG Question 1: During a practice audit of patients over 75 years taking 10 or more regular medications, you identify several patients who would benefit from structured medication reviews. You are prioritising which patients to review first based on risk stratification. According to best practice guidance on medication reviews in primary care, which patient characteristic indicates HIGHEST priority for urgent structured medication review?
- A. A patient taking 15 medications who has been stable on the same regimen for 3 years with no recent adverse events
- B. A patient recently discharged from hospital with five new medications added to their existing regimen (Correct Answer)
- C. A patient taking multiple high-risk medications including warfarin, methotrexate, and lithium who attends regular monitoring
- D. A patient who has reached the age of 75 and is now eligible for routine medication review under the Quality and Outcomes Framework
- E. A patient with declining renal function (eGFR decreased from 68 to 54 over 12 months) taking eight regular medications
Multimorbidity Explanation: ***A patient recently discharged from hospital with five new medications added to their existing regimen***
- **Hospital discharge** is a high-risk transition point where medication errors, **therapeutic duplication**, and communication gaps between primary and secondary care frequently occur.
- National guidelines (NICE and NHS England) prioritize patients with recent **regimen changes** for urgent review to ensure **medication reconciliation** and prevent adverse drug events.
*A patient taking 15 medications who has been stable on the same regimen for 3 years with no recent adverse events*
- While **polypharmacy** (taking 10+ medications) is a risk factor, clinical **stability** over three years suggests the regimen is currently tolerated and less urgent than an acute transition.
- This patient requires a review to reduce **pill burden**, but they do not meet the criteria for "highest priority" compared to a post-discharge patient.
*A patient taking multiple high-risk medications including warfarin, methotrexate, and lithium who attends regular monitoring*
- Patients on **narrow therapeutic index** drugs require careful supervision, but the fact they are attending **regular monitoring** indicates their risk is already being managed systematically.
- Urgent intervention is typically reserved for those with **unmonitored** high-risk drugs or those experiencing active complications.
*A patient who has reached the age of 75 and is now eligible for routine medication review under the Quality and Outcomes Framework*
- Routine eligibility based on age or **QOF requirements** is a preventative and administrative trigger rather than an urgent clinical risk stratification.
- This represents a **scheduled review** rather than an urgent need driven by clinical instability or a high-risk event like hospitalization.
*A patient with declining renal function (eGFR decreased from 68 to 54 over 12 months) taking eight regular medications*
- A gradual decline in **eGFR** over a year requires dose adjustments for renally cleared drugs, but the **12-month timeline** makes it less acute than a post-hospital change.
- This scenario necessitates a review to prevent **nephrotoxicity**, but it does not represent the immediate high-risk window associated with discharge reconciliation.
Multimorbidity UK Medical PG Question 2: A 75-year-old man with COPD (post-bronchodilator FEV1 42% predicted), ischaemic heart disease, atrial fibrillation, and type 2 diabetes attends for medication review. He is on multiple inhalers: tiotropium, salmeterol/fluticasone 25/250 twice daily, and salbutamol as needed. Other medications include apixaban, bisoprolol, ramipril, atorvastatin, and metformin. He has had two exacerbations requiring oral steroids in the past year, the last one being 8 months ago. His current COPD symptoms are well-controlled with no exacerbations recently. Sputum cultures from his last exacerbation grew Pseudomonas aeruginosa. Which change to his inhaler therapy is MOST appropriate?
- A. Add a regular azithromycin prophylaxis regimen due to previous Pseudomonas infection
- B. Switch from salmeterol/fluticasone to a triple therapy inhaler (LABA/LAMA/ICS combination) (Correct Answer)
- C. Stop inhaled corticosteroids and continue bronchodilators only, given limited recent exacerbations
- D. Reduce fluticasone dose to minimise steroid-related adverse effects including pneumonia risk
- E. Add regular nebulised colistin for Pseudomonas suppression in COPD
Multimorbidity Explanation: ***Switch from salmeterol/fluticasone to a triple therapy inhaler (LABA/LAMA/ICS combination)***- The patient is already on **triple therapy** (LAMA, LABA, ICS) using separate devices. Combining these into a single **LABA/LAMA/ICS** inhaler simplifies the regimen and improves **medication adherence**.- For patients with severe COPD (FEV1 42%) and frequent exacerbations (two in the past year), **triple therapy** is indicated to reduce exacerbation rates, and using a single device is preferred.*Add a regular azithromycin prophylaxis regimen due to previous Pseudomonas infection*- **Azithromycin prophylaxis** is typically considered for frequent exacerbators despite **optimal inhaled therapy**, often after ensuring the current inhaler regimen is maximally effective and simplified.- While the patient has a history of exacerbations, the initial step should be to optimize and streamline their primary inhaled maintenance therapy before adding prophylactic antibiotics, which carry risks of **antibiotic resistance** and side effects.*Stop inhaled corticosteroids and continue bronchodilators only, given limited recent exacerbations*- Stopping **inhaled corticosteroids (ICS)** is inappropriate in this patient due to a history of **frequent exacerbations** (two in the past year) and severe airflow limitation.- Discontinuing ICS in patients with a history of frequent exacerbations is associated with an increased risk of **future exacerbations** and worsening lung function.*Reduce fluticasone dose to minimise steroid-related adverse effects including pneumonia risk*- While **pneumonia risk** is a known concern with ICS, this patient's history of two exacerbations in the past year indicates a need for continued, effective anti-inflammatory therapy.- Reducing the **fluticasone dose** would be a step-down approach, which is not recommended for a patient who is a frequent exacerbator and has severe COPD.*Add regular nebulised colistin for Pseudomonas suppression in COPD*- **Nebulised colistin** is primarily used for chronic suppression of **Pseudomonas aeruginosa** in conditions like **bronchiectasis** or **cystic fibrosis**.- Its routine use for Pseudomonas suppression in COPD, especially without co-existing bronchiectasis, is not a standard recommendation in current guidelines and lacks strong evidence.
Multimorbidity UK Medical PG Question 3: You are conducting a structured medication review for an 80-year-old man with heart failure (NYHA class II), type 2 diabetes, chronic kidney disease stage 3b (eGFR 38 ml/min/1.73m²), and benign prostatic hyperplasia. He lives alone and manages his medications independently using a dosette box filled by his daughter. He takes 13 different medications at various times throughout the day. He mentions he sometimes forgets his evening doses and finds the regimen 'complicated'. Which approach BEST addresses medication adherence in this context according to principles of medicines optimisation?
- A. Simplify the regimen by switching to once-daily preparations where possible and aligning administration times (Correct Answer)
- B. Arrange for a district nurse to visit twice daily to supervise medication administration
- C. Provide detailed written instructions about each medication and the importance of adherence
- D. Reduce the total number of medications by stopping those not providing immediate symptom relief
- E. Arrange urgent assessment of his cognitive function as non-adherence suggests early dementia
Multimorbidity Explanation: ***Simplify the regimen by switching to once-daily preparations where possible and aligning administration times***- Medicines optimisation principles prioritise reducing **regimen complexity** and dosing frequency to improve **treatment adherence**, especially in elderly patients with polypharmacy.- Aligning schedules and using **once-daily formulations** addresses the patient's specific struggle with evening doses and his perception that the regimen is too 'complicated'.*Arrange for a district nurse to visit twice daily to supervise medication administration*- This is an overly restrictive and **paternalistic intervention** that undermines the patient's independence while he is still largely capable of self-care.- Resource-heavy interventions like **supervised administration** are typically reserved for patients with severe cognitive or physical impairments who cannot use aids independently.*Provide detailed written instructions about each medication and the importance of adherence*- While education is helpful, it does not solve the **structural complexity** of a 13-medication regimen with multiple dosing times throughout the day.- Information alone is often insufficient to overcome **unintentional non-adherence** caused by a burdensome and confusing schedule.*Reduce the total number of medications by stopping those not providing immediate symptom relief*- Arbitrarily stopping medications based only on immediate symptoms ignores **preventative treatments** (like those for CKD or heart failure) that reduce long-term morbidity.- While **deprescribing** is a key part of review, it must be based on a clinical risk-benefit analysis rather than simply the absence of immediate symptoms.*Arrange urgent assessment of his cognitive function as non-adherence suggests early dementia*- Forgetting parts of an exceptionally complex **13-medication regimen** is frequently a result of the system's burden rather than an indicator of **cognitive impairment**.- Formal cognitive assessment may be considered later, but the immediate priority should be the **optimisation** of a demonstrably difficult medication schedule.
Multimorbidity UK Medical PG Question 4: A 70-year-old woman with rheumatoid arthritis, osteoporosis, hypertension, and gastro-oesophageal reflux disease attends for review. She takes: methotrexate 15mg weekly, folic acid 5mg weekly (taken day after methotrexate), prednisolone 5mg daily, alendronic acid 70mg weekly, omeprazole 20mg daily, amlodipine 10mg daily, and calcium/vitamin D daily. Blood tests show: Hb 102 g/L (MCV 88 fL), WCC 3.8 × 10⁹/L, platelets 156 × 10⁹/L, ALT 68 U/L (previously 32), eGFR 58 ml/min/1.73m². Which aspect of her medication regimen requires MOST urgent attention?
- A. The alendronic acid and omeprazole combination reducing bisphosphonate absorption
- B. The low haemoglobin suggesting methotrexate-induced bone marrow suppression requiring urgent cessation
- C. The elevated ALT indicating methotrexate hepatotoxicity requiring dose reduction or cessation (Correct Answer)
- D. The combination of prednisolone and alendronic acid requiring additional osteoporosis monitoring
- E. The declining renal function requiring methotrexate dose adjustment or alternative DMARD
Multimorbidity Explanation: ***The elevated ALT indicating methotrexate hepatotoxicity requiring dose reduction or cessation***- The patient's **ALT** has doubled from baseline (32 to 68 U/L), which is a significant signal for **methotrexate hepatotoxicity** according to clinical monitoring guidelines.- Immediate action is required to withhold the medication and re-test **liver function** within 1-2 weeks to prevent progressive hepatic damage.*The alendronic acid and omeprazole combination reducing bisphosphonate absorption*- While some PPIs may theoretically affect mineral absorption, this combination is common and not an **urgent clinical concern** compared to organ toxicity.- The patient is already being treated for osteoporosis, and the **GORD** management is a higher symptomatic priority than minor absorption variances.*The low haemoglobin suggesting methotrexate-induced bone marrow suppression requiring urgent cessation*- The **Hb of 102 g/L** with a normal **MCV of 88 fL** (normocytic) often reflects **anaemia of chronic disease** in a patient with rheumatoid arthritis.- Although **bone marrow suppression** is a risk, the WCC and platelets remain within relatively safe ranges, making this less urgent than the liver function abnormalities.*The combination of prednisolone and alendronic acid requiring additional osteoporosis monitoring*- The patient is already appropriately prescribed **alendronic acid** and **calcium/vitamin D** to mitigate the bone loss risk associated with **prednisolone**.- While monitoring via **DEXA scans** is necessary in the long term, it does not constitute an "urgent" priority in the context of acute lab changes.*The declining renal function requiring methotrexate dose adjustment or alternative DMARD*- An **eGFR of 58 ml/min/1.73m²** indicates mild renal impairment but is still above the critical threshold (usually 30 ml/min) for absolute cessation.- While renal function affects **methotrexate clearance**, the current level does not require immediate discontinuation as urgently as the rising **ALT** levels do.
Multimorbidity UK Medical PG Question 5: A practice pharmacist is conducting a quality improvement project on anticholinergic burden in elderly patients with multimorbidity. She identifies a 73-year-old man taking 12 medications with a total Anticholinergic Cognitive Burden (ACB) score of 6. His medications include amitriptyline 50mg nocte for neuropathic pain, tolterodine 4mg for overactive bladder, lansoprazole 30mg, co-codamol 30/500, atorvastatin, ramipril, bisoprolol, aspirin, and metformin. He reports feeling 'foggy-headed' and has had two falls. Which intervention would have the GREATEST impact on reducing anticholinergic burden?
- A. Switch tolterodine to mirabegron, a beta-3 agonist with no anticholinergic activity
- B. Replace amitriptyline with duloxetine for neuropathic pain management
- C. Stop lansoprazole as proton pump inhibitors contribute to cognitive impairment
- D. Address both amitriptyline and tolterodine simultaneously by switching to alternatives (Correct Answer)
- E. Reduce co-codamol dose as opioids can contribute to cognitive impairment
Multimorbidity Explanation: ***Address both amitriptyline and tolterodine simultaneously by switching to alternatives***
- **Amitriptyline** and **tolterodine** are both high-burden drugs (ACB score of 3 each); replacing both is the most effective way to reduce the total **Anticholinergic Cognitive Burden (ACB)** score from 6 to near zero.
- Addressing both medications directly targets the patient's symptoms of **cognitive impairment ('foggy-headed')** and **falls**, which are classic adverse effects of high anticholinergic exposure in the elderly.
*Switch tolterodine to mirabegron, a beta-3 agonist with no anticholinergic activity*
- Switching **tolterodine** alone would only reduce the ACB score by 3, leaving the patient with a still-significant burden from the **amitriptyline**.
- While **mirabegron** is an excellent alternative for **overactive bladder** without anticholinergic effects, it does not address the neuropathic pain medication's contribution to the score.
*Replace amitriptyline with duloxetine for neuropathic pain management*
- Replacing **amitriptyline** with **duloxetine** (which has minimal to no anticholinergic activity) reduces the score by 3 but ignores the impact of **tolterodine**.
- Although this is a clinically sound step for **neuropathic pain**, a singular drug change is less impactful than a comprehensive review of all high-ACB agents.
*Stop lansoprazole as proton pump inhibitors contribute to cognitive impairment*
- **Lansoprazole** (a proton pump inhibitor) does not contribute to the **Anticholinergic Cognitive Burden** score, so stopping it would not improve the ACB metrics.
- While PPIs have other long-term risks, they are not the primary cause of **anticholinergic-mediated** delirium or falls in this scenario.
*Reduce co-codamol dose as opioids can contribute to cognitive impairment*
- **Co-codamol** (codeine/paracetamol) can cause sedation and falls due to its **opioid** component, but it does not carry a weight on the **ACB scale**.
- Reducing the dose may help general alertness but will not lower the **anticholinergic-specific** burden that this quality improvement project aims to address.
Multimorbidity UK Medical PG Question 6: A 76-year-old woman with dementia (MMSE 18/30), Parkinson's disease, type 2 diabetes, and recurrent falls is brought by her daughter for medication review. Current medications include: co-careldopa 25/100 three times daily, ropinirole 8mg three times daily, quetiapine 25mg twice daily, metformin 500mg twice daily, gliclazide 40mg twice daily, alendronic acid 70mg weekly, calcium/vitamin D, and PRN paracetamol. She has had three falls in the past two months. Her daughter reports increasing confusion and hallucinations. Blood glucose monitoring shows values between 4.8-8.2 mmol/L. Which medication intervention should be prioritised?
- A. Reduce co-careldopa dose as dopaminergic medications contribute to hallucinations and falls
- B. Stop quetiapine immediately as antipsychotics worsen Parkinson's disease motor symptoms
- C. Review and rationalise diabetes medications given risk of hypoglycaemia contributing to falls
- D. Stop alendronic acid as bisphosphonates increase fall risk in elderly patients
- E. Reduce ropinirole as dopamine agonists cause hallucinations and should be withdrawn first (Correct Answer)
Multimorbidity Explanation: ***Reduce ropinirole as dopamine agonists cause hallucinations and should be withdrawn first***
- **Dopamine agonists** like ropinirole carry a much higher risk of inducing **visual hallucinations** and confusion compared to levodopa, especially in patients with cognitive impairment.
- Management guidelines for Parkinson’s psychosis prioritize the **gradual withdrawal** of dopamine agonists before altering levodopa therapy to minimize neuropsychiatric side effects while preserving motor function.
*Reduce co-careldopa dose as dopaminergic medications contribute to hallucinations and falls*
- While levodopa can contribute to hallucinations, it is the **gold standard** for motor control and is less frequently the primary cause of psychosis than dopamine agonists.
- Reducing **co-careldopa** before reducing ropinirole might severely compromise the patient's mobility and increase the risk of **motor fluctuations**.
*Stop quetiapine immediately as antipsychotics worsen Parkinson's disease motor symptoms*
- **Quetiapine** is one of the few antipsychotics used in Parkinson's because it has a low affinity for **D2 receptors**, making it less likely to worsen motor symptoms.
- Abruptly stopping it may cause a rebound of psychiatric symptoms; the priority is to remove the **precipitating factor** (ropinirole) rather than the treatment for the symptoms.
*Review and rationalise diabetes medications given risk of hypoglycaemia contributing to falls*
- The patient's blood glucose readings (4.8-8.2 mmol/L) indicate **tight control**, but she is not currently experiencing clinical **hypoglycemia** that would explain acute hallucinations.
- While preventing hypoglycemia is important for fall prevention, it does not address the primary complaint of **visual hallucinations** and increasing confusion.
*Stop alendronic acid as bisphosphonates increase fall risk in elderly patients*
- **Alendronic acid** is used to prevent fractures and does not have a known association with an increased **risk of falls** or hallucinations.
- It is generally continued in elderly patients with high fracture risk unless there are specific contraindications like **esophageal disorders** or severe renal impairment.
Multimorbidity UK Medical PG Question 7: A 68-year-old man with ischaemic heart disease, permanent atrial fibrillation, type 2 diabetes, and osteoarthritis takes: aspirin 75mg, apixaban 5mg twice daily, bisoprolol 5mg, atorvastatin 80mg, metformin 1g twice daily, gliclazide 80mg twice daily, and paracetamol as required. He has no history of stenting or acute coronary syndrome in the past 12 months. His most recent echocardiogram shows LVEF 55% with no wall motion abnormalities. His CHA₂DS₂-VASc score is 5. Which medication change is MOST appropriate?
- A. Stop apixaban and continue aspirin alone for cardiovascular protection
- B. Stop aspirin as dual antiplatelet and anticoagulation increases bleeding risk without additional benefit (Correct Answer)
- C. Continue both medications as dual therapy is indicated in atrial fibrillation with ischaemic heart disease
- D. Stop both aspirin and apixaban and commence warfarin for better control
- E. Reduce apixaban to 2.5mg twice daily when used in combination with aspirin
Multimorbidity Explanation: ***Stop aspirin as dual antiplatelet and anticoagulation increases bleeding risk without additional benefit***- In patients with stable **ischaemic heart disease** (beyond 12 months from an ACS event or stenting) and **atrial fibrillation**, monotherapy with an **oral anticoagulant** is sufficient and preferred.- The addition of **aspirin** to a **DOAC** like apixaban significantly increases the risk of **major bleeding** and intracranial haemorrhage without providing additional cardiovascular protection.*Stop apixaban and continue aspirin alone for cardiovascular protection*- This patient has a **CHA₂DS₂-VASc score of 5**, indicating a high risk of thromboembolic stroke that requires formal **anticoagulation**.- Aspirin is inferior to **apixaban** for stroke prevention in atrial fibrillation and would leave the patient inadequately protected.*Continue both medications as dual therapy is indicated in atrial fibrillation with ischaemic heart disease*- Dual therapy is only indicated for a limited period (usually **12 months**) following **Acute Coronary Syndrome (ACS)** or **stenting**.- Chronic dual therapy is avoided in stable disease because the **bleeding risk** outweighs the benefits of combined antiplatelet and anticoagulant action.*Stop both aspirin and apixaban and commence warfarin for better control*- There is no clinical indication to switch to **warfarin**, as **DOACs** like apixaban are generally preferred due to better safety profiles and no requirement for **INR monitoring**.- Stopping both medications would leave the patient at an unacceptably high risk of both **myocardial infarction** and **ischaemic stroke**.*Reduce apixaban to 2.5mg twice daily when used in combination with aspirin*- Dose reduction of **apixaban** is based on specific criteria (age ≥80, weight ≤60kg, or creatinine ≥133 μmol/L), not on the concurrent use of **antiplatelets**.- Using a sub-therapeutic dose of an anticoagulant increases the risk of **thromboembolism** while still carrying a bleeding risk when combined with aspirin.
Multimorbidity UK Medical PG Question 8: During a structured medication review using the STOPP/START criteria for a 71-year-old woman, you identify she takes co-codamol 30/500 four times daily for chronic lower back pain, alongside atorvastatin, ramipril, and bisoprolol. She mentions she has been constipated for several weeks and also takes senna tablets daily. She has no history of major surgery or inflammatory spinal disease, and her back pain has been present for 18 months. Her renal function and liver function are normal. Which action represents BEST practice according to deprescribing principles?
- A. Switch co-codamol to tramadol to reduce constipation while maintaining analgesia
- B. Add a stimulant laxative such as sodium picosulfate to manage opioid-induced constipation
- C. Gradually reduce and stop codeine while optimising non-opioid analgesia and addressing pain holistically (Correct Answer)
- D. Continue current regimen but refer for specialist pain management assessment
- E. Switch to modified-release morphine for more consistent pain control
Multimorbidity Explanation: ***Gradually reduce and stop codeine while optimising non-opioid analgesia and addressing pain holistically*** - The **STOPP criteria** highlight long-term **opioid use** for chronic non-cancer pain as potentially inappropriate, given its limited long-term efficacy and significant side effects, like constipation, especially in elderly patients.- Best practice involves a **gradual taper** of the opioid to prevent withdrawal, while transitioning to **non-pharmacological interventions** (e.g., exercise, physiotherapy) and optimizing **non-opioid analgesia**.
*Switch co-codamol to tramadol to reduce constipation while maintaining analgesia*- **Tramadol** is also an **opioid** with a similar risk profile for **constipation**, dependence, and cognitive impairment, particularly in the elderly.- This option represents an **opioid rotation**, which does not address the core issue of potentially **inappropriate long-term opioid prescribing** for chronic primary pain.
*Add a stimulant laxative such as sodium picosulfate to manage opioid-induced constipation*- This is an example of a **prescribing cascade**, where a new medication is introduced to manage the side effect of an existing, potentially unnecessary drug.- While providing symptomatic relief, it fails to address the underlying problem of the **opioid-induced constipation** and the continued use of an opioid identified as inappropriate by the **STOPP criteria**.
*Continue current regimen but refer for specialist pain management assessment*- Maintaining a regimen with **potentially inappropriate medication** (long-term high-dose opioid) delays crucial clinical action to reduce harm, which can often be initiated in primary care.- The **STOPP/START criteria** aim to empower clinicians to take immediate action on deprescribing opportunities to mitigate **adverse drug events**.
*Switch to modified-release morphine for more consistent pain control*- Upgrading to a **stronger, long-acting opioid** like morphine for chronic non-cancer pain is contrary to current guidelines and significantly increases the risk of **opioid toxicity** and dependence, especially in an elderly patient.- Modified-release strong opioids are not recommended for routine management of **chronic lower back pain** without clear structural pathology and should be avoided in deprescribing.
Multimorbidity UK Medical PG Question 9: A 74-year-old man attends for medication review. He has heart failure (LVEF 32%), atrial fibrillation, type 2 diabetes, stage 3b CKD (eGFR 36 ml/min/1.73m²), and benign prostatic hyperplasia. Current medications: bisoprolol 10mg, ramipril 10mg, furosemide 40mg, spironolactone 25mg, apixaban 5mg twice daily, metformin 1g twice daily, empagliflozin 10mg, finasteride 5mg, tamsulosin 400mcg, atorvastatin 80mg. Blood tests show potassium 5.4 mmol/L, sodium 134 mmol/L, urea 12.8 mmol/L, creatinine 168 μmol/L (stable). He reports good symptom control but occasional dizziness on standing. Which represents the BEST management approach?
- A. Stop spironolactone due to hyperkalaemia risk and continue other heart failure medications
- B. Reduce ramipril to 5mg daily to decrease potassium and improve renal function
- C. Stop empagliflozin as it may be contributing to hyperkalaemia and renal impairment
- D. Continue current regimen with close monitoring as benefits outweigh risks (Correct Answer)
- E. Stop tamsulosin as it may be causing orthostatic hypotension and reduce polypharmacy
Multimorbidity Explanation: ***Continue current regimen with close monitoring as benefits outweigh risks***
- The patient is receiving the **'quadruple therapy'** for heart failure with reduced ejection fraction (HFrEF), which significantly reduces **mortality** and hospitalizations.
- A potassium of 5.4 mmol/L is acceptable for transition to long-term monitoring as it remains **below 5.5 mmol/L**, and his creatinine/eGFR values are stable and within an acceptable range for these medications.
*Stop spironolactone due to hyperkalaemia risk and continue other heart failure medications*
- Guidance suggests keeping mineralocorticoid receptor antagonists (MRAs) unless potassium consistently **exceeds 5.5 mmol/L**, as they provide a crucial **survival benefit**.
- Routine cessation for mild elevations prevents the patient from receiving life-prolonging **aldosterone blockade**.
*Reduce ramipril to 5mg daily to decrease potassium and improve renal function*
- Reducing the **ACE inhibitor** dose for a stable eGFR of 36 ml/min/1.73m² and mild hyperkalemia would result in sub-optimal **neurohormonal blockade**.
- Stable renal impairment (Stage 3b CKD) is not an indication for dose reduction if the serum **creatinine rise** from baseline is less than 30%.
*Stop empagliflozin as it may be contributing to hyperkalaemia and renal impairment*
- **SGLT2 inhibitors** like empagliflozin actually provide **renoprotective** benefits and reduce the risk of more severe hyperkalemia when used with MRAs.
- There is no clinical indication to stop this medication as it is indicated for both **HFrEF** and **type 2 diabetes** with CKD.
*Stop tamsulosin as it may be causing orthostatic hypotension and reduce polypharmacy*
- While **tamsulosin** can cause orthostatic hypotension, the patient's dizziness is occasional, and his overall symptom control is good.
- Stopping an effective medication for **benign prostatic hyperplasia** (BPH) without a clear, overriding reason may worsen urinary symptoms, and dizziness could also stem from other cardiovascular medications.
Multimorbidity UK Medical PG Question 10: According to the Beers Criteria for potentially inappropriate medication use in older adults, which of the following medications should be avoided in elderly patients regardless of diagnosis or condition?
- A. Long-acting benzodiazepines such as diazepam and chlordiazepoxide (Correct Answer)
- B. Non-selective beta-blockers in patients with peripheral vascular disease
- C. First-generation antihistamines in patients with cognitive impairment
- D. Proton pump inhibitors when used for longer than 8 weeks
- E. Thiazide diuretics in patients with a history of gout
Multimorbidity Explanation: ***Long-acting benzodiazepines such as diazepam and chlordiazepoxide***
- The **Beers Criteria** recommends avoiding these medications in all older adults due to their **long half-lives**, which lead to accumulation and prolonged effects.
- Usage significantly increases the risk of **falls, fractures, cognitive impairment**, and motor vehicle accidents in the elderly population.
*Non-selective beta-blockers in patients with peripheral vascular disease*
- This is a **condition-specific** precaution rather than a general category for avoidance in all older adults regardless of diagnosis.
- While they can theoretically worsen claudication, they are not listed as **potentially inappropriate medications** for all geriatric patients in the primary Beers list.
*First-generation antihistamines in patients with cognitive impairment*
- While these are generally avoided due to **anticholinergic effects**, the option specifies a condition (cognitive impairment) rather than a universal avoidance.
- The Beers Criteria actually recommends avoiding all highly anticholinergic **first-generation antihistamines** for most older adults, but the long-acting benzodiazepine choice is the most definitive answer for universal avoidance in this context.
*Proton pump inhibitors when used for longer than 8 weeks*
- PPIs are listed under the Beers Criteria to be avoided beyond **8 weeks** of use due to risks of **Clostridioides difficile** infection and bone loss.
- This is a **duration-specific** recommendation rather than a medication that must be avoided entirely regardless of the clinical situation or time frame.
*Thiazide diuretics in patients with a history of gout*
- This represents a **disease-drug interaction** where the medication may exacerbate a specific pre-existing condition by increasing **uric acid** levels.
- Thiazides are not on the list of medications to be avoided in all elderly patients; they remain first-line therapy for **hypertension** in many older adults.
More Multimorbidity UK Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
